Kristina Burow and Paul Berns, Neumora

ARCH un­veils its Re­al­ly Big Neu­ro­science Com­pa­ny with $500M, an Am­gen deal and eyes on de­pres­sion, Alzheimer's and a lot more

ARCH Ven­ture is dou­bling — and tripling and qua­dru­pling — down on the be­lief that the 2020s will be neu­ro­science’s decade.

The VC firm, known for pe­ri­od­i­cal­ly launch­ing mas­sive com­pa­nies from scratch, an­nounced on Thurs­day the cre­ation of Neumo­ra, a biotech ARCH’s part­ners be­lieve can fi­nal­ly crack a set of well-known neu­rode­gen­er­a­tive and psy­chi­atric dis­eases that have long elud­ed drug­mak­ers. The com­pa­ny, whose ex­is­tence was first re­port­ed by End­points News in Au­gust, emerges from stealth with $500 mil­lion in the bank — $400 mil­lion from ARCH and oth­er VCs and $100 mil­lion eq­ui­ty in­vest­ment as part of a col­lab­o­ra­tion with Am­gen.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.